Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
Hirai H, Takahashi-Suziki I, Shimomura T, Fukasawa K, Machida T, Takaki T, Kobayashi M, Eguchi T, Oki H, Arai T, Ichikawa K, Hasako S, Kodera T, Kawanishi N, Nakatsuru Y, Kotani H, Iwasawa Y. Hirai H, et al. Among authors: hasako s. Invest New Drugs. 2011 Aug;29(4):534-43. doi: 10.1007/s10637-009-9384-8. Epub 2010 Jan 19. Invest New Drugs. 2011. PMID: 20084424
Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.
Hirai H, Shimomura T, Kobayashi M, Eguchi T, Taniguchi E, Fukasawa K, Machida T, Oki H, Arai T, Ichikawa K, Hasako S, Haze K, Kodera T, Kawanishi N, Takahashi-Suziki I, Nakatsuru Y, Kotani H, Iwasawa Y. Hirai H, et al. Among authors: hasako s. Cell Cycle. 2010 Apr 15;9(8):1590-600. doi: 10.4161/cc.9.8.11306. Epub 2010 Apr 15. Cell Cycle. 2010. PMID: 20372067
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.
Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K. Hasako S, et al. Mol Cancer Ther. 2018 Aug;17(8):1648-1658. doi: 10.1158/1535-7163.MCT-17-1206. Epub 2018 May 10. Mol Cancer Ther. 2018. PMID: 29748209
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS. Udagawa H, et al. Among authors: hasako s. Mol Cancer Res. 2019 Nov;17(11):2233-2243. doi: 10.1158/1541-7786.MCR-19-0419. Epub 2019 Aug 29. Mol Cancer Res. 2019. PMID: 31467113 Free PMC article.
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer.
Yasumoto M, Sakamoto E, Ogasawara S, Isobe T, Kizaki J, Sumi A, Kusano H, Akiba J, Torimura T, Akagi Y, Itadani H, Kobayashi T, Hasako S, Kumazaki M, Mizuarai S, Oie S, Yano H. Yasumoto M, et al. Among authors: hasako s. Cancer Med. 2017 Jan;6(1):235-244. doi: 10.1002/cam4.959. Epub 2016 Nov 28. Cancer Med. 2017. PMID: 27891760 Free PMC article.